BRAF/MEK inhibitor-induced tumor lysis syndrome in a patient with malignant melanoma

被引：0
|
作者：
Maeda, Shintaro [1 ]
Imazaki, Katsuya [1 ]
Shimizu, Kyoko [1 ]
Oishi, Kyosuke [1 ]
Hamaguchi, Yasuhito [1 ]
Matsushita, Takashi [1 ]
机构：
[1] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Fac Med, Dept Mol Pathol Skin, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan
来源：
JOURNAL OF DERMATOLOGY | 2025年 / 52卷 / 03期
关键词：
D O I：
10.1111/1346-8138.17507
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：e242 / e243
页数：2
相关论文
共 50 条
  • [41] Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case report
    Kattan, Joseph
    Kattan, Clarisse
    Farhat, Fadi
    Assi, Tarek
    ANTI-CANCER DRUGS, 2019, 30 (10) : 1052 - 1054
  • [42] Pathological complete response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with unresectable BRAF V600E-mutant malignant melanoma of the gallbladder
    Yu, Zhou
    Quiroz, Elisa
    Shen, Yulei
    Jaiyesimi, Ishmael A.
    ONCOTARGETS AND THERAPY, 2018, 11 : 8723 - 8728
  • [43] ID3, a Neural Crest associated Gene, is involved in BRAF Inhibitor-induced Resistance to Melanoma
    Larribere, L.
    Sachindra, S.
    Novak, D.
    Wu, H.
    Hueser, L.
    Grandos-Blanco, K.
    Orouji, E.
    Utikal, J.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 24 - 24
  • [44] Steroid-induced tumor lysis syndrome in a patient with preleukemia
    Yang, SS
    Chau, T
    Dai, MS
    Lin, SH
    CLINICAL NEPHROLOGY, 2003, 59 (03) : 201 - 205
  • [45] Spontaneous Tumor Lysis Syndrome In A Patient With Metastatic Melanoma Presenting In Septic Shock
    Teba, C.
    Thornton, G.
    Fouladpour, N.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [46] Tumor Lysis Syndrome Presenting in a Patient with Metastatic Melanoma Treated with Radiation Therapy
    Dar, Lior
    Gendelman, Omer
    Amital, Howard
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2014, 16 (07): : 456 - 457
  • [47] Growth-Inhibitory and Antiangiogenic Activity of the MEK Inhibitor PD0325901 in Malignant Melanoma with or without BRAF Mutations
    Ciuffreda, Ludovica
    Del Bufalo, Donatella
    Desideri, Marianna
    Di Sanza, Cristina
    Stoppacciaro, Antonella
    Ricciardi, Maria Rosaria
    Chiaretti, Sabina
    Tavolaro, Simona
    Benassi, Barbara
    Bellacosa, Alfonso
    Foa, Robin
    Tafuri, Agostino
    Cognetti, Francesco
    Anichini, Andrea
    Zupi, Gabriella
    Milella, Michele
    NEOPLASIA, 2009, 11 (08): : 720 - U21
  • [48] Advanced malignant BRAFV600-mutant Melanoma BRAF/MEK-Inhibitor Combination shows sustained Efficacy
    Bischoff, Angelika
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (10) : 542 - 542
  • [49] PSEUDOVITELLIFORM MACULOPATHY SECONDARY TO BRAF AND MEK INHIBITORS IN A PATIENT WITH METASTASIC MELANOMA
    Alba-Linero, C.
    Rocha De Lossada, C.
    Delgado-Fernandez, A. S.
    Jodar-Marquez, M.
    Calvo De Mora, M. Rodriguez
    Berciano-Guerrero, M. A.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2019, 33 (05): : 1497 - 1500
  • [50] Exacerbation of Kaposi sarcoma following BRAF/MEK inhibitor therapy in a melanoma patient: a case report and mechanistic insight
    Tsimpidakis, Antonios
    Koumprentziotis, Ioannis-Alexios
    Mastoraki, Evanthia
    Plaka, Michaella
    Gogas, Helen
    Stratigos, Alexander
    Nikolaou, Vasiliki
    MELANOMA RESEARCH, 2024, 34 (05) : 469 - 471
12345